Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401374 | 0.87 | CASP1 (0.41) | CASP1 | |
| SCHEMBL18328212 | 0.81 | MAPT (0.41) | CASP1 | |
| SCHEMBL18159719 | 0.81 | TDP1 (0.39) | CASP1 | |
| SCHEMBL991835 | 0.80 | CASP1 (0.43) | CASP1 | |
| SCHEMBL10882651 | 0.80 | CASP1 (0.43) | CASP1 | |
| SCHEMBL8869145 | 0.80 | CASP1 (0.43) | CASP1 | |
| SCHEMBL1282757 | 0.80 | TSHR (0.45) | CASP1 | |
| SCHEMBL10888856 | 0.79 | CASP1 (0.59) | CASP1 | |
| SCHEMBL10884952 | 0.79 | CASP1 (0.59) | CASP1 | |
| SCHEMBL9241574 | 0.79 | CASP1 (0.59) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340756-B1 | NOVEL BETA-LACTAM COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7163936-B2 | β-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1340756-A1 | NOVEL BETA-LACTAM COMPOUNDS AND PROECSS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | MRPL21, MCRS1, RPS4X | CASP1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.